History of Formation

Affitech AS was established in 1997 by a group of Norwegian and German scientists on the basis of the acquisition of the worldwide exclusive rights from German Cancer Center, Heidelberg, Germany of “Breitling “ IP which covered phagemid display of human antibodies.

In May 2009, Affitech AS was combined with Pharmexa A/S to form Affitech A/S.


  NOTICE OF ANNUAL GENERAL MEETING To the shareholders of Affitech A/S (CVR no 14 53 83 72) Notice is hereby...
Affitech A/S Annual Report 2013 is now published